Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

Sales: The California-based device maker is pinning its hopes on Stelo, its recently launched device for adults aged 18 and ...

If you have $2,000 to invest right now, here are two top growth stocks to consider. DexCom (NASDAQ: DXCM) is one of the ...

A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...

DexCom projects 2025 revenue of $4.6 billion, representing 14% growth. This forecast assumes strong demand for CGM systems, expanded reimbursement coverage, and a second-half launch of a 15-day G7 ...

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...

The Stelo has a 15-day wear time before the sensor needs to be replaced, similar to DexCom's flagship G7 CGM, which has a 10-day wear time. While short-term factors such as above-average ...

Reports Q4 revenue $1.11B, consensus $1.10B. “In 2024, we implemented our largest US commercial sales force expansion, had two major product ...

DexCom, Inc. DXCM is scheduled to release fourth-quarter 2024 results on Feb. 13, after the closing bell. In the last ...